Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AMY ELIZABETH ROBERTS

Allopathic & Osteopathic Physicians Family Medicine

NPI
1003894775
CMS profile
272479
Location
TOWN AND COUNTRY, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$4,463.39

11 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $3,061.00 1
Travel and Lodging $930.60 2
Food and Beverage $471.79 8

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Astellas Pharma US Inc $4,377.34 6
ABBVIE INC. $45.29 2
OptiNose US, Inc. $16.98 1
Currax Pharmaceuticals LLC $12.11 1
Lilly USA, LLC $11.67 1

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AMY ELIZABETH ROBERTS

NPI 1003894775 · CMS profile ID 272479

Allopathic & Osteopathic Physicians / Family Medicine

TOWN AND COUNTRY, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1003894775?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AMY ELIZABETH ROBERTS, NPI 1003894775, CMS profile ID 272479. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003894775?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). AMY ELIZABETH ROBERTS, NPI 1003894775, CMS profile ID 272479. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003894775?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
AMY ELIZABETH ROBERTS, NPI 1003894775, CMS profile ID 272479, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1003894775?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

11 matching records · $4,463.39 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 11 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–11 of 11.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Astellas Pharma US Inc $299.7511/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038677223 CMS
Astellas Pharma US Inc $3,061.0011/18/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038677225 CMS
Astellas Pharma US Inc $276.6411/17/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038677089 CMS
Astellas Pharma US Inc $653.9611/17/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038677093 CMS
Currax Pharmaceuticals LLC $12.1110/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 925764177 CMS
OptiNose US, Inc. $16.9810/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 928113285 CMS
Astellas Pharma US Inc $58.7210/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940297949 CMS
Lilly USA, LLC $11.6710/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917860651 CMS
Astellas Pharma US Inc $27.2708/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940258709 CMS
ABBVIE INC. $20.7505/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891460769 CMS
ABBVIE INC. $24.5401/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891460767 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $625.85 43
PY2020 $497.46 33
PY2021 $585.99 36
PY2022 $4,463.39 11
PY2023 $209.74 9
PY2024 $900.78 10
PY2025 $221.61 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $659,355.35 57
PY2024 Principal investigator $1,673,854.87 52
PY2023 Principal investigator $1,696,177.01 1,469

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

52 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $400.00 12/30/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147137348
Principal investigator 1 ModernaTX, Inc. $405,513.24 12/27/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147137310
Principal investigator 1 ModernaTX, Inc. $600.00 12/24/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147137336
Principal investigator 1 ModernaTX, Inc. $15,136.22 12/06/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147136184
Principal investigator 1 ModernaTX, Inc. $9,631.70 12/04/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147137282
Principal investigator 1 ModernaTX, Inc. $18,879.81 12/02/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147136182
Principal investigator 1 ModernaTX, Inc. $438,729.02 11/27/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147137216
Principal investigator 1 ModernaTX, Inc. $21,364.16 11/27/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147137230
Principal investigator 1 ModernaTX, Inc. $538.12 11/21/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147137224
Principal investigator 1 ModernaTX, Inc. $1,810.90 11/06/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147137194
Principal investigator 1 ModernaTX, Inc. $29,663.34 10/28/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147137128
Principal investigator 1 ModernaTX, Inc. $300.00 10/23/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147136050
Principal investigator 1 ModernaTX, Inc. $50.00 10/07/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147137142
Principal investigator 1 ModernaTX, Inc. $13,000.00 10/03/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147137090
Principal investigator 1 ModernaTX, Inc. $4,528.12 10/03/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147137130
Principal investigator 1 ModernaTX, Inc. $2,000.00 10/01/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147136052
Principal investigator 1 ModernaTX, Inc. $1,650.00 10/01/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147136054
Principal investigator 1 ModernaTX, Inc. $1,500.00 10/01/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147136056
Principal investigator 1 ModernaTX, Inc. $1,719.36 09/25/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147137032
Principal investigator 1 ModernaTX, Inc. $200.00 09/20/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147137020
Principal investigator 1 ModernaTX, Inc. $2,572.49 09/18/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1147136952
Principal investigator 1 ModernaTX, Inc. $10,215.96 09/18/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147137004
Principal investigator 1 ModernaTX, Inc. $1,200.00 09/16/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136984
Principal investigator 1 ModernaTX, Inc. $598.68 09/10/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147136942
Principal investigator 1 ModernaTX, Inc. $114,309.13 09/02/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136964
Principal investigator 1 ModernaTX, Inc. $1,896.94 08/07/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136892
Principal investigator 1 ModernaTX, Inc. $57,963.52 08/01/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136874
Principal investigator 1 ModernaTX, Inc. $4,600.00 07/19/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1147136322
Principal investigator 1 ModernaTX, Inc. $72,496.58 06/27/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136834
Principal investigator 1 ModernaTX, Inc. $65,624.11 06/10/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136814
Principal investigator 1 ModernaTX, Inc. $2,050.00 06/05/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136794
Principal investigator 1 ModernaTX, Inc. $80.00 05/31/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136762
Principal investigator 1 ModernaTX, Inc. $1,650.78 05/29/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136754
Principal investigator 1 ModernaTX, Inc. $325.00 05/17/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147135750
Principal investigator 1 ModernaTX, Inc. $11,916.43 05/15/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136716
Principal investigator 1 ModernaTX, Inc. $1,200.00 05/02/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136694
Principal investigator 1 ModernaTX, Inc. $2,151.36 04/24/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1147136646
Principal investigator 1 ModernaTX, Inc. $144,867.65 04/17/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147135674
Principal investigator 1 ModernaTX, Inc. $28,151.48 03/28/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136594
Principal investigator 1 ModernaTX, Inc. $140.00 03/25/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136578
Principal investigator 1 ModernaTX, Inc. $75,312.30 03/21/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136558
Principal investigator 1 ModernaTX, Inc. $134.80 03/12/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136626
Principal investigator 1 ModernaTX, Inc. $500.00 03/06/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136538
Principal investigator 1 ModernaTX, Inc. $1,635.10 03/01/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136522
Principal investigator 1 ModernaTX, Inc. $55,178.46 02/26/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136458
Principal investigator 1 ModernaTX, Inc. $7,424.52 02/16/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136432
Principal investigator 1 ModernaTX, Inc. $3,938.66 02/12/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136414
Principal investigator 1 ModernaTX, Inc. $2,600.00 02/07/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136400
Principal investigator 1 ModernaTX, Inc. $300.00 01/24/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147135485
Principal investigator 1 ModernaTX, Inc. $100.00 01/24/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136278
Principal investigator 1 ModernaTX, Inc. $876.33 01/17/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147135493
Principal investigator 1 ModernaTX, Inc. $34,630.60 01/16/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136262